Aphria Inc., a global cannabis-lifestyle consumer packaged goods company, announced Denise Faltischek, Aphria’s Chief Strategy Officer, will also assume the role of Managing Director of Aphria Germany, effective January 23, 2021, reporting to Irwin D. Simon, Aphria’s Chairman and Chief Executive Officer. Ms. Faltischek joined Aphria in September 2019 with extensive consumer-packaged goods experience and expertise leading over 50 acquisitions. She leads Aphria’s global business strategy and oversees Aphria’s medical and international business segments as well as quality function.
Irwin D. Simon commented, “Denise has been instrumental in leading our strategic initiatives in Canada and internationally as we’ve scaled our operations. We are excited for her to further expand her role by also leading our day-to-day operations in Germany where she has worked closely with the team since joining Aphria. In Germany, we are leveraging our strong medical platform and our multifaceted international operation, which combines in-country cultivation, import permits and large distribution infrastructure to increase access and availability to high-quality, consistent medical cannabis for patients. In establishing our international footprint in Germany, we invested in the completion of our in-country cultivation facility and distribution network in Neumünster, Germany.”
Mr. Simon, continued, “In Europe, upon the closing of our business combination with Tilray, we will enhance our footprint with five strong brands to help us establish an unrivaled European platform, including two production facilities and a robust and flexible supply chain given Tilray’s EU-GMP facility in Portugal. Tilray has a leading medical cannabis operation in Europe that will benefit our existing medical sales and distribution as well as extend CC Pharma’s medical cannabis offering with access to over 13,000 pharmacies in Germany.”
Aphria remains on-track to be the first licensed producer to cultivate medical cannabis in Germany with the opening of its cultivation facility in Neumünster, Germany, which is awaiting EU-GMP certification. It is expected that the first harvest will occur in the first quarter of calendar year 2021.
“We believe the European Union continues to have many robust growth opportunities for Aphria and Germany represents the most sought-after market within those countries,” said Ms. Faltischek. “We’ve recently achieved several significant milestones in Germany that strengthen our position as a leading cannabis company in the European Union, including the completion of our first certified EU-GMP shipment of dried flower from our Canadian Aphria One facility to our German subsidiary, CC Pharma, as well as the introduction of Aphria Strong 9, our first THC-dominant medical cannabis flower. We also recently completed our first shipment of certified EU-GMP medical cannabis oils for the German market. Going forward, we remain well positioned for long-term growth in Germany and Europe.”
Aphria Inc. is a global cannabis-lifestyle consumer packaged goods company with operations in Canada, United States, Europe and Latin America, that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body and soul and invoke a sense of wellbeing. For more information, visit: aphriainc.com